For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Cencora, Inc. (COR) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-07): Designation Watch · Gem Score +19 (−100…+100 Quality+Value blend) · Quality 39 · Value 5 · Sentiment -9 (timing only, not weighted) · Composite fair value $251.70 vs $316.32 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Cencora, Inc.
COR NYSECencora, Inc. is a global pharmaceutical solutions organization that serves as a critical link between drug manufacturers, healthcare providers, pharmacies, and patients. Headquartered in Conshohocken, Pennsylvania, Cencora focuses on sourcing and distributing branded, generic, and specialty pharmaceutical products, along with over-the-counter healthcare items and related medical supplies. The company plays a central role in the healthcare supply chain by providing secure, reliable distribution and logistics services, as well as commercialization support for brand and specialty therapies. Beyond distribution, Cencora offers consulting, technology, analytics, and market access solutions designed to enhance provider efficiency and support patient access to complex treatments. Its operations span human and animal health, reflecting a broad presence across hospitals, health systems, community practices, specialty pharmacies, and veterinary channels. Today, Cencora is recognized as a leading partner for pharmaceutical innovators and healthcare organizations, helping ensure that therapies can reach the right patients in numerous markets worldwide.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 7.96
Total Equity: $1.75B
Shares: 195,214,000
Total Debt: $7.66B
Cash: $4.36B
EBITDA: $3.68B
Total Debt: $7.66B
Cash: $4.36B
Revenue: $321.33B
Revenue: $321.33B
Revenue: $321.33B
Total Equity: $1.75B
Tax Rate: 30.6%
Equity: $1.75B
Total Debt: $7.66B
Cash: $4.36B
Current Liabilities: $57.82B
Long-Term Debt: $7.54B
Total Debt: $7.66B
Total Equity: $1.75B
Shares: 195,214,000
Shares: 195,214,000
CapEx: -$667.98M
Shares: 195,214,000
Stock Price: $316.13
Net Income: $1.55B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 19, 2026 9:24am (49d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Cost of Revenue | $207.0B | $230.3B | $253.2B | $284.0B | $309.9B |
| Gross Profit | $6.9B | $8.3B | $9.0B | $9.9B | $11.5B |
| Operating Expenses | $4.6B | $5.9B | $6.6B | $7.7B | $8.8B |
| Operating Income | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net Income | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| EBITDA | $2.9B | $3.1B | $3.3B | $3.3B | $3.7B |
| EPS | $7.48 | $8.15 | $8.62 | $7.60 | $8.02 |
| EPS (Diluted) | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
Balance Sheet (Annual)
Last updated: Aug 19, 2026 12:20am (49d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.5B | $3.4B | $2.6B | $3.1B | $4.4B |
| Total Current Assets | $38.8B | $39.6B | $42.8B | $47.7B | $52.2B |
| Total Assets | $57.3B | $56.6B | $62.6B | $67.1B | $76.6B |
| Current Liabilities | $41.4B | $43.5B | $48.8B | $54.3B | $57.8B |
| Long-Term Debt | $6.4B | $4.6B | $4.1B | $3.8B | $7.5B |
| Total Liabilities | $56.8B | $56.5B | $61.9B | $66.3B | $74.8B |
| Total Equity | $584.4M | $71.3M | $666.3M | $786.7M | $1.7B |
| Retained Earnings | $1.7B | $3.0B | $4.3B | $5.4B | $6.5B |
Cash Flow (Annual)
Last updated: Aug 19, 2026 9:24am (49d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.7B | $2.7B | $3.9B | $3.5B | $3.9B |
| Capital Expenditure | -$438.2M | -$496.3M | -$458.4M | -$487.2M | -$668.0M |
| Free Cash Flow | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
| Acquisitions (net) | -$5.6B | -$133.8M | -$1.4B | -$69.8M | -$4.1B |
| Net Debt Issued / (Repaid) | $2.3B | $155.2M | -$653.8M | $25.8M | $3.2B |
| Dividends Paid | -$366.6M | -$391.7M | -$398.8M | -$416.2M | -$437.1M |
| Stock Buybacks | -$82.2M | -$483.7M | -$1.2B | -$1.5B | -$435.5M |
| Net Change in Cash | -$1.5B | $523.4M | -$840.7M | $545.0M | $1.1B |
Growth Trends (YoY %)
Last updated: Aug 19, 2026 9:24am (49d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +11.5% | +9.9% | +12.1% | +9.3% |
| Gross Profit Growth | +19.5% | +8.0% | +10.6% | +15.8% |
| Operating Income Growth | +0.5% | -1.1% | -7.1% | +20.8% |
| Net Income Growth | +10.3% | +2.7% | -13.5% | +3.0% |
| EBITDA Growth | +7.0% | +8.0% | -1.1% | +12.6% |
Dividend History (Last 20)
Last updated: Aug 19, 2026 12:18am (49d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-14 | $0.60 | — | — | — |
| 2026-05-15 | $0.60 | — | — | — |
| 2026-02-13 | $0.60 | — | — | — |
| 2025-11-14 | $0.60 | — | — | — |
| 2025-08-15 | $0.55 | — | — | — |
| 2025-05-16 | $0.55 | — | — | — |
| 2025-02-14 | $0.55 | — | — | — |
| 2024-11-15 | $0.55 | — | — | — |
| 2024-08-09 | $0.51 | — | — | — |
| 2024-05-09 | $0.51 | — | — | — |
| 2024-02-08 | $0.51 | — | — | — |
| 2023-11-10 | $0.51 | — | — | — |
| 2023-08-10 | $0.49 | — | — | — |
| 2023-05-11 | $0.49 | — | — | — |
| 2023-02-09 | $0.49 | — | — | — |
| 2022-11-10 | $0.49 | — | — | — |
| 2022-08-12 | $0.46 | — | — | — |
| 2022-05-13 | $0.46 | — | — | — |
| 2022-02-11 | $0.46 | — | — | — |
| 2021-12-01 | $1.27 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-03 02:02A +1σ run of quarters pays -21%; a −1σ run costs 56%. Ratio -0.4:1 (μ 7.3%, σ 3.5% , 16 pairs).
Older method (repeat-worst-quarter): 18.1 : 1
| Case | Growth | Margin | Fair value | vs price ($316.32) |
|---|---|---|---|---|
| Bull — recovery | +7% | 17.3% | $4,105.41 | +1198% |
| Base — stabilizes | +5% | 15.0% | $3,288.51 | +940% |
| Bear — keeps slipping | +2% | 12.8% | $2,572.06 | +713% |
| Stress — last quarter repeats | +6% | 0.4% | $107.30 | -66% |
| Upside — a +1σ run of quarters (v2) | +11% | 0.9% | $250.96 | -21% |
| Stress — a −1σ run of quarters (v2) | +4% | 0.6% | $137.67 | -56% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-19 12:26The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting with the raw tape: revenue compounded from $214B (FY21) to $321B (FY25), a 10.7% CAGR that's genuinely impressive for a $60B distributor — but net income went $1.54B → $1.51B → $1.75B → $1.51B → $1.55B over the same window. Zero earnings growth on 50% revenue growth. That's the entire story and every model dances around it. Gross margin has actually crept up (3.24% → 3.57%) but operating margin fell from 1.10% to 0.82% as SG&A scaled faster than gross profit. The Q1 FY26 print ($84.75B rev, $763M NI, 0.9% margin) is a deceleration from the March quarter's 2.1% margin blip and shows the pattern continuing. TTM NI is roughly $2.63B, putting real P/E closer to 23x — not the 40x headline, because the reported figure lags a good year.
The balance sheet is where the pre-flight and market-forces notes are directionally right but understated. $1.75B of equity supporting $321B of revenue and $7.66B of debt is a working-capital machine, not a fortress — the P/B of 35x is a mathematical artifact of buybacks eroding book, not a quality signal. Current ratio 0.90 means Cencora is structurally funded by supplier float; any disruption to payment terms (manufacturer consolidation, GLP-1 mix distortion, a single large customer renegotiation like the Walgreens overhang) hits liquidity before it hits the P&L. ROIC of 36% is real but reflects the asset-light distributor model, not durable pricing power — McKesson and Cardinal earn similar returns and the three of them cannot all simultaneously expand margin against consolidating pharmacy buyers.
Now the models. The synthesis verdict of "undervalued, signal-adjusted FV $366.70" is the one I most distrust. A DCF on a business with -5.6% earnings CAGR and -3.6% FCF CAGR that spits out a 16% discount is a DCF that's extrapolating revenue growth and assuming margin mean-reversion — both of which the five-year record refutes. The thesis evaluation (-22, bear-tilted) and market-forces (neutral with downside skew) are closer to what the numbers actually say. The narrative layer's "anchored, steady-compounder, minimal intensity" read is the most honest: this stock isn't mispriced by story, it's priced by index flows and defensive rotation. Insider activity — three P-Purchases in May/June 2026 totaling ~8,550 shares — is directionally positive but small ($2.7M total) against a $60B cap; it's not a signal, it's noise dressed up as one. The "Net Insider Buying" secondary signal is overweighting a rounding error.
Contrarian read: if you strip the buyback tailwind (share count compression is doing most of the EPS work), organic earnings are flat-to-declining while the stock re-rated from ~15x to ~23x normalized earnings over three years. That's not a discount waiting to close — that's a multiple that already expanded on the specialty-pharma narrative and now needs actual margin delivery to justify itself. The Q2 FY26 2.1% margin was almost certainly a one-time item (mix, legal settlement reversal, or tax) given Q1 and Q3 both printed sub-1%; anyone modeling that as normalized is fooling themselves. Fair value on 20x $2.6B normalized earnings = $52B, or roughly $273/share. To get to $366 you need to believe operating margin expands 30-50bps sustainably, which requires either specialty mix doing what it hasn't done in five years or AI/analytics revenue that doesn't exist in the segment reporting. I dissent from the synthesis. The thesis-evaluation engine got closer to right by being bearish, but even -22 undersells how much of the current price depends on a margin story the P&L keeps refusing to write. This isn't a short — the business is real, FCF is real ($3.21B), the dividend is covered, and it will grind with the sector — but paying $316 for flat earnings and a 90bps current ratio is not "undervalued," it's paying a quality premium for stability that the balance sheet doesn't actually provide.
GPT Reading
What stands out is that Cencora is being valued like a high-quality compounder while the reported earnings stream still looks more like a highly efficient toll collector with messy, low-visibility quarterly profit conversion. Revenue has been excellent: annual sales rose from $213.99B in 2021 to $321.33B in 2025, a 10%+ CAGR, and the latest four reported quarters sum to roughly $332.8B, so top-line momentum remains intact. But the income statement below gross profit is much less convincing. Gross margin improved from 3.2% in 2021 to 3.6% in 2025, yet operating margin is still only 0.82% and net margin 0.48%. Quarterly net margins swing from 2.1% in 2026-03 to 0.7% in 2025-12 to negative 0.4% in 2025-09. That is not what I want to see in a stock at 39.7x earnings and 17.5x EV/EBITDA. The market is effectively capitalizing a distribution business on the assumption that its earnings volatility is optical and its cash generation is the truth. Maybe—but at $316, that assumption is doing a lot of work.
The bull case has one real anchor: cash flow is materially better than GAAP earnings. In 2025, net income was $1.55B, operating cash flow was $3.88B, and free cash flow was $3.21B. On today’s $60.33B market cap, that is about a 5.3% FCF yield, respectable for a defensive healthcare infrastructure name with durable demand. Net debt is manageable at about $3.3B after offsetting $7.66B debt with $4.36B cash, so this is not a balance-sheet emergency despite the scary-looking 4.38x debt/equity ratio. Equity is only $1.75B, which makes P/B and ROE close to useless here; the 35x P/B is a denominator artifact, not evidence of market euphoria by itself. More importantly, operating income has not grown much—$2.35B in 2021, $2.37B in 2022, down to $2.34B in 2023, then up to $2.63B in 2025—so the business has needed enormous revenue growth just to eke out modest EBIT growth. That is fine for a stable distributor at a market multiple; it is not fine for one trading at a premium multiple.
The biggest contradiction in the packet is the “undervalued” valuation output versus the economics of the business. A company at 0.2x sales can screen cheap, but for distributors that only matters if margin durability and capital efficiency convert tiny spreads into dependable EPS growth. Here, earnings CAGR over the period is negative, FCF CAGR is also negative, and the most recent quarterly earnings trend is lumpy rather than compounding. If I annualize the last four reported quarterly net incomes, I get about $2.62B, which would make the stock look closer to 23x run-rate earnings—not absurd, but still full for a sub-1% net margin distributor whose annual net income has mostly sat in a $1.5B-$1.75B band for five years. Put differently, if normalized earnings power is around $2.4B-$2.7B and normalized FCF is around $3.0B-$3.3B, the current valuation already discounts years of reliable mid- to high-single-digit compounding. I don’t see enough evidence of that in the reported operating history.
The strongest case against my caution is that I may be anchoring too hard on GAAP net income in a business where quarter-to-quarter profitability is routinely distorted by one-offs, tax items, or working-capital timing, while the underlying machine is actually becoming better. Revenue is still growing near 9%-10%, gross profit dollars rose from $6.94B in 2021 to $11.48B in 2025, and operating income did reach a record $2.63B last year. If specialty mix is improving and scale advantages are widening, then today’s 0.82% operating margin may not be the ceiling. In that scenario, even 20-30 basis points of sustained margin improvement on a $320B+ revenue base would be meaningful; 0.2% of sales is more than $640M of operating profit. Add decent buybacks and steady cash conversion, and a 5% FCF yield can support acceptable returns even without multiple expansion. Insider buying, while small relative to market cap, also leans supportive rather than alarming.
What would change my mind is evidence that Cencora can translate its scale into clean, repeatable profit growth rather than episodic earnings spikes. Specifically, I would want to see two or three consecutive quarters with operating margin holding above 1.0% and net income running at least $700M-$800M without unusual volatility, alongside full-year free cash flow comfortably above $3.5B. If annual operating income can move from $2.63B toward $3.0B while revenue growth stays high single digits, then the premium multiple becomes easier to defend. Conversely, another year where revenue grows from, say, $321B toward $340B+ but operating income and FCF stay essentially flat would confirm that this is a terrific business operationally but an over-earning stock financially.
Grok Reading
Cencora’s numbers describe a high-velocity tollbooth that is growing the top line while quietly leaking profitability. Revenue has compounded from $214B in FY2021 to $321B in FY2025—a clean 10.7% CAGR—and the last four quarters still print $78–86B each with recent year-over-year growth near 9%. Yet operating income has been stuck in a $2.2–2.6B band for five years, net income has gone nowhere ($1.54B → $1.55B), and both earnings and free-cash-flow CAGRs are negative (–5.6% and –3.6%). The June 2026 quarter’s $763M of net income on $84.8B of sales is a 0.9% margin; the $1.64B print the prior quarter was an obvious outlier at 2.1%. Strip that noise and you are looking at a sub-1% net-margin distributor whose gross margin has compressed to 3.6%. The market is paying 40× trailing annual earnings and roughly 23× a generous TTM figure that still embeds that one fat quarter—rich for a business whose earnings power has not scaled with volume.
The balance sheet magnifies the discomfort. Equity is only $1.75B against $7.66B of debt and a current ratio of 0.90; the 35× price-to-book and 89% ROE are artifacts of that razor-thin equity cushion, not evidence of super-normal returns. Free cash flow of $3.21B is the genuine bright spot—roughly a 5.3% yield on the $60B equity value—and the company converts earnings into cash cleanly. That cash-flow quality, plus modest insider open-market buying and a defensive demographic backdrop, is what keeps the stock from looking broken. But cash flow is also declining on a multi-year basis, and the equity base leaves almost no margin for error if working-capital or litigation shocks appear.
I therefore read the stock as modestly overvalued at $316. The valuation-synthesis composite that points to $367 assumes growth the income statement has so far refused to deliver and treats the specialty-mix story as already earned margin. The thesis-evaluation layer is closer to the truth: structural margin compression and share loss to McKesson are the dominant forces, and a 40× multiple (or even mid-20s on cleaned-up TTM) prices in a defensive utility that the actual earnings trajectory has never been. At roughly 0.2× sales the multiple looks optically cheap only because sales are enormous and almost pure pass-through; on earnings and FCF the premium to a mature earner is real.
The strongest counter-argument is straightforward. Revenue growth remains durable, FCF still exceeds $3B, ROIC prints an eye-catching 36%, the payout ratio is only 28%, and the aging-population / specialty-pharmacy mix shift could finally lift operating margins above 1% and re-rate the stock. If the $1.64B quarter was the start of a new run-rate rather than a one-off, trailing power is closer to $2.5B and the multiple compresses into the low-20s—territory where a high-quality distributor can reasonably sit. Insiders have been net buyers, and the narrative layer itself is subdued, so there is no frothy cult premium to deflate. Those points keep me from a high-conviction short; they do not overturn the five-year evidence that volume growth is not translating into earnings growth.
I would flip constructive on two concrete developments: two consecutive quarters of operating margin at or above 1.1% with revenue still growing high-single-digits, and clear evidence that Cencora is holding or taking share in specialty distribution rather than ceding ground. Absent that, the path of least resistance is multiple compression toward the mid-20s on normalized earnings, implying material downside from $316.
Qwen Reading local experiment · off-panel
The number that decides this case is not the 39x P/E or the 35x P/B — both are artifacts of a $1.75B equity base sitting under $7.66B of debt on a $321B revenue company. The meaningful multiple is EV/FCF: $60.33B market cap minus $4.36B cash plus $7.66B debt gives an enterprise value of $63.6B, and against $3.21B of free cash flow that is roughly 20x. For a pharmaceutical distributor with a 0.5% net margin, 20x EV/FCF sits at the upper end of the 12–18x range that characterises the sector's three large players. The P/S of 0.19x is unremarkable; the P/E of 39x is a mirage created by dividing a $60B market cap by $1.55B of net income that a single bad quarter can erase, as the $339.7M loss in Q3 2025 demonstrated.
Revenue is the genuine strength here. The five-year CAGR of 10.7% (from $214B in FY2021 to $321B in FY2025) is impressive at this scale, and the most recent year-over-year comparison — $84.75B in Q2 2026 versus $80.66B a year earlier, +5.1% — confirms the trend is still positive. But the deceleration is real: Q1 2026 grew only 3.9% year-over-year, and the "decelerating" tag in the momentum block is correct. Operating income did recover to $2.63B in FY2025 from $2.18B in FY2024, the best figure in the five-year window, yet net income of $1.55B remains below the $1.75B posted in FY2023. The gap is interest expense on the $7.66B debt load and the Q3 2025 charge. Normalising for that one-time item, clean annual earnings are closer to $1.8–1.9B, which puts the effective P/E at roughly 32–33x — still expensive for a business whose net margin hovers between 0.5% and 1.0%.
The balance sheet is the part of the data that the prior models underweight. A current ratio of 0.90 is normal for a high-velocity distributor, and operating cash flow of $3.88B comfortably covers the $668M capex and debt service. But $1.75B of equity against $7.66B of debt (D/E 4.4x) means there is almost no cushion if a second consecutive loss quarter hits, or if a credit event in the healthcare sector tightens refinancing terms. The 89% ROE that the canonical metrics report is not a quality signal; it is leverage arithmetic on a tiny equity base. The "razor-thin equity cushion" language in the Market Forces detail is the one sentence in the prior outputs that correctly identifies the structural risk, even though the overall signal is labelled "Neutral."
The prior models are internally contradictory. The Valuation Synthesis declares the stock "undervalued" with a composite fair value of $292.49 — which is 7% *below* the $316.13 price — then applies a "signal adjustment" to push it to $366.70, a 16% premium. That is not a valuation; that is a mood. The Thesis Evaluation scores the stock −22 on a −100 to +100 scale with "Structural Margin Compression" as the top bear at weight 72, yet the raw data shows operating income at a five-year high and revenue still growing 5% year-over-year. The margin compression thesis has not yet materialised in the tape. The earnings CAGR of −5.6% in the momentum block does not reconcile with the annual figures, which show net income essentially flat from $1.54B (FY2021) to $1.55B (FY2025); that negative CAGR is a base-year artefact, not a trend. The insider activity — three small P-Purchases totalling 8,550 shares (roughly $2.7M) and seven A-Awards, zero open-market sales — is compensation mechanics on a $60B float, not a conviction signal in either direction.
The strongest case against a "fairly valued" call is the margin fragility. A 0.5% net margin means a 10% increase in distribution costs, a single manufacturer pricing dispute, or a government formulary shift can wipe out a full year of earnings in one quarter, as Q3 2025 showed. At 20x EV/FCF, the market is paying for a level of earnings stability that the income statement does not support. A careful bear would also note that the 10.7% revenue CAGR is heavily driven by drug-price inflation rather than volume growth, and that the specialty-pharmacy mix-shift narrative that justified a premium five years ago has not produced the promised operating-margin expansion — operating margin in FY2025 was 0.82%, barely above the 0.74% of FY2021. The revenue is growing, but the profit per dollar of revenue is not.
What would change my mind in either direction: a Q3 2026 print showing net margin above 1.2% for two consecutive quarters would validate the specialty-mix thesis and push the fair EV/FCF toward 22–24x, making $316 a buy. Conversely, a second loss quarter, a debt refinancing at materially higher spreads, or revenue growth decelerating below 3% year-over-year would confirm the margin-compression bear case and pull fair value toward $250–270. The stock is not broken, but it is not cheap either, and the thin equity means the downside is sharper than the upside.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Cencora is a scaled pharmaceutical distributor running the classic thin-margin, high-turnover model: revenue compounded from $214B (2021) to $321B (2025), roughly 10.7% CAGR, on gross margins in a tight 3.2-3.6% band and operating margins between 0.7% and 1.1%. Net income has been range-bound around $1.5-1.75B while FCF has stepped up meaningfully to $3.0-3.4B in the last three years, with OCF/NI of 2.07x and accruals of -2.6% of assets - earnings are backed by cash and then some, largely a function of working-capital dynamics in drug distribution. Beneish M at -2.54 and Altman Z at 4.82 corroborate clean books. Capital allocation is disciplined: diluted share count fell from 208.5M to 195.2M (-1.6% CAGR), SBC is a rounding error at 0.1% of revenue, and buybacks run nearly 6x SBC - per-share value is being concentrated. The offset is a levered balance sheet: net debt of ~$3.3B against $4.36B of liquid cash, so the balance sheet is a constraint rather than a cushion, though $3.2B of annual FCF services it comfortably. Operating margin has drifted from 1.1% to 0.8% even as revenue grew ~50%, which is the one quiet negative - scale is not producing operating leverage, consistent with a distribution business where customer/supplier bargaining power caps upside. Insider activity shows two genuine open-market purchases by Durcan (~$2.2M combined) and a smaller Tyler buy, which is a mild positive signal against routine awards and tax withholdings.
Verify before trusting this (5)
- Customer concentration - how much revenue tied to Walgreens and top-3 customers per 10-K
- Impact and remaining contingent liability from the historical opioid settlement obligations
- Debt maturity schedule and covenant terms behind the $3.3B net debt
- Segment mix - contribution of higher-margin specialty/animal health vs. core distribution
- Whether operating margin compression is mix, contract renegotiations, or one-off items
The composite fair value sits at $292 (roughly 8% below the $316.32 price), while the signal-adjusted FV of $367 implies about 16% upside. The DCF anchor at $378 is the bull leg and the EPV floor at $137 is a reminder that on a no-growth, thin-margin snapshot this distribution business is worth far less than today's price - a healthy caution given operating margin has drifted from 1.1% to 0.8%. The anchored PE of $277 is arguably the most defensible marker for a mature, low-growth middleman, and it sits about 12% below spot.
Verify before trusting this (4)
- Operating margin trajectory in next 2 quarters - is the 1.1% to 0.8% slide stabilizing?
- Specialty and biosimilar mix contribution to gross profit dollars
- Buyback pace and any change in capital allocation guidance
- Exposure to any single large customer renewal (Walgreens contract terms)
Cencora sits in the sentiment dead zone: a steady-compounder archetype with minimal narrative intensity and low cult factor means the market simply isn't telling a hot story about this name in either direction. With a 0.57 beta, the modestly risk-on tape (VIX 15.8, S&P near highs) barely reaches this stock - it neither participates in melt-ups nor gets whipsawed on risk-off days. Macro is explicitly neutral for the profile, so there's no rate or cycle push to speak of. The lingering pressure is stock-specific: the May 2026 -17.4% gap on the Q2 miss is still the freshest sentiment imprint, and drug-distribution as a cohort carries a slow bleed of headline risk around pricing, government policy, and manufacturer/pharmacy leverage. Set against that, the narrative durability is genuinely high - this is infrastructure the market grudgingly respects - which puts a floor under sentiment even when nobody is excited. Net: crosswinds roughly cancel. No dominant force is pressing the tape here; the stock is being marked to fundamentals, not to a story or a regime. That's a Balanced read with a very slight lean to headwind from the unresolved earnings-miss memory.
Verify before trusting this (4)
- Next earnings print - does the market forgive the May miss or extend the de-rating
- Any US drug-pricing or PBM policy headlines that could revive distributor-cohort bear framing
- Analyst target revisions post-May: are they still trimming or have estimates stabilized
- Sector rotation into defensives if VIX pushes above 20 - would turn low-beta into a modest tailwind
Global drug consumption keeps rising on aging populations, GLP-1 adoption and a dense specialty/biologic pipeline; those molecules still need a licensed, capital-intensive, temperature-controlled channel, and three US distributors own it. The world's changes — more specialty, more complexity, more regulatory scrutiny of the supply chain — mostly deepen the need for the intermediary rather than disintermediate it, and direct-to-patient manufacturer channels remain small and still lean on distributor logistics. The genuine forward pressure is on the pricing regime: government price-setting and MFN-style rules shrink the dollar base fees attach to, pushing distributors to volume/service-based contracts. Neutral macro (10y 4.72, positively sloped curve) is largely irrelevant to script volumes, but higher rates raise the cost of the working capital this model floats.
When we made this prediction on Aug 19, 2026, COR was $316.32. We expect it to be $333.00 by Feb 2027, and we consider it great value under $275.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 19, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
trailing_eps
flips up 10%
adjusted_pe
flips up 10%